$CBIO

H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.

Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care

Stifel maintained a Buy rating and $28 target on Crescent Biopharma (NASDAQ:CBIO) after FDA clearance of its CR-002 drug. The stock trades at $13.94, down 28% in six months. Stifel expects trial data in 2027. Crescent raised $143.7M in a public offering. H.C. Wainwright upgraded CBIO to Buy with a $36 target.

H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy with a $36.00 price target, citing potential catalysts in 2027. The stock is currently trading at $13.94. The firm highlighted the company's antibody-drug conjugate pipeline and recent public offering raising $143.7 million. CBIO's balance sheet shows more cash than debt, a strength for a clinical-stage biotech.

Crescent Biopharma (Nasdaq: CBIO) announced FDA clearance for its IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC for solid tumors. The Phase 1/2 APOLLO trial will start in Q4 2026, with initial data expected in H2 2027. The trial will enroll 200+ patients across the US, Europe, and Asia Pacific.

Crescent Biopharma (CBIO) presented its oncology strategy at the Morgan Stanley conference, focusing on CR-001, a PD-1/VEGF bispecific. The company reported $305M in cash, a runway into 2H 2028, and expects key data in Q1 2027. Shares closed at $19.68, up 1.39%, with a market cap of $849.6M and a 66% YTD return. Management acknowledged clinical development risks and potential overvaluation.

Crescent Biopharma (CBIO) will present at two healthcare conferences in September 2026. The company's clinical pipeline includes CR-001, CR-002, and CR-003. Key milestones include ASCEND trial data in 2027 and an IND application for CR-002 in mid-2026. Q2 2026 net loss was $24.8 million. Wedbush maintains an Outperform rating and $27 price target. CBIO stock is down 1.22% at $20.63.

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treate